Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas

British Journal of Cancer

Volumn 100, Issue 11, 2009, Pages 1777-1783

  Moura, M M ^a   Cavaco, B M ^a   Pinto, A E ^b   Domingues, R ^a   Santos, J R ^b   Cid, M O ^b   Bugalho, M J ^a,b,c   Leite, V ^a,b,c  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^b Instituto Portugus de Oncologia de Lisboa Francisco Gentil EPE   (Portugal)

^c UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Genetic screening; Prognosis; RET proto oncogene; Somatic mutation; Sporadic medullary thyroid carcinoma

Indexed keywords

CALCITONIN;

ADULT; AGED; ARTICLE; CALCITONIN BLOOD LEVEL; CLINICAL FEATURE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE RET; PRIORITY JOURNAL; PROTO ONCOGENE; SOMATIC MUTATION; THYROID MEDULLARY CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS;

EID: 67349168712     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605056     Document Type: Article

References (41)

1. Andre S, Pinto AE, Laranjeira C, Quaresma M, Soares J (2007) Male and female breast cancer - differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis. Pathobiology 74: 323-327
2. Asai N, Iwashita T, Matsuyama M, Takahashi M (1995) Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15: 1613-1619
3. Bockhorn M, Frilling A, Kalinin V, Schröder S, Broelsch CE (1999) No correlation between RET immunostaining and the codon 918 mutation in sporadic medullary thyroid carcinoma. Langenbecks Arch Surg 384: 60-64
4. Bugalho MJ, Coelho I, Sobrinho LG (2000) Somatic trinucleotide change encompassing codons 882 and 883 of the RET proto-oncogene in a patient with sporadic medullary thyroid carcinoma. Eur J Endocrinol 142: 573-575
5. Bugalho MJ, Frade JP, Santos JR, Limbert E, Sobrinho L (1997) Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain. Eur J Endocrinol 136: 423-426
6. Carling T (2005) Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr Opin Oncol 17: 7-12
7. de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM (2006) RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 27: 535-560
8. DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Vol. 8, IARC Press: Lyon, p 50
9. Dvoráková S, Václavíková E, Sýkorová V, Dusková J, Vlcek P, Ryska A, Novák Z, Bendlová B (2006) New multiple somatic mutations in the RET proto-oncogene associated with a sporadic medullary thyroid carcinoma. Thyroid 16: 311-316
10. Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Novak Z, Duskova J, Ryska A, Laco J, Cap J, Kodetova D, Kodet R, Krskova L, Vlcek P, Astl J, Vesely D, Bendlova B (2008) Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 284: 21-27
11. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93: 682-687
12. Eng C (1999) RET proto-oncogene in the development of human cancer. J Clin Oncol 17: 380-393
13. Evans DB, Shapiro SE, Cote GJ (2007) Invited commentary: medullary thyroid cancer: the importance of RET testing. Surgery 141: 96-99
14. Frank-Raue K, Rondot S, Schulze E, Raue F (2007) Change in the spectrum of RET mutations diagnosed between 1994 and 2006. Clin Lab 53: 273-282
15. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA (1983) Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31: 1333-1335
16. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Höppener JW, van Amstel HK, Romeo G, Lips CJ, Buys CH (1994) A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367: 375-376
17. Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83: 2638-2648
18. Imyanitov EN, Grigoriev MY, Gorodinskaya VM, Kuligina ES, Pozharisski KM, Togo AV, Hanson KP (2001) Partial restoration of degraded DNA from archival paraffin-embedded tissues. Biotechniques 31: 1000, 1002
19. Jhiang SM, Fithian L, Weghorst CM, Clark OH, Falko JM, O'Dorisio TM, Mazzaferri EL (1996) RET mutation screening in MEN2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma. Thyroid 6: 115-121
20. Jindrichova S, Kodet R, Krskova L, Vlcek P, Bendlova B (2003) The newly detected mutations in the RET proto-oncogene in exon 16 as a cause of sporadic medullary thyroid carcinoma. J Mol Med 81: 819-823
21. Lindsay S (1970) Microspectrophotometric measurements of deoxyribo-nucleic acid in human thyroid carcinomas. Surg Gynecol Obstet 131: 905-913
22. Marini F, Falchetti A, Del Monte F, Carbonell Sala S, Tognarini I, Luzi E, Brandi ML (2006) Multiple endocrine neoplasia type 2. Orphanet J Rare Dis 1: 45
23. Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, Delbridge L, Eng C, Robinson BG (1996) Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 44: 249-257
24. Marsh DJ, Theodosopoulos G, Martin-Schulte K, Richardson AL, Philips J, Röher HD, Delbridge L, Robinson BG (2003) Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 88: 1866-1872
25. Marx SJ (2005) Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 5: 367-375
26. Matias-Guiu X, DeLellis R, Moley JF, Gagel RF, Albores-Saavedra J, Bussolati G, Kaserer K, Williams ED, Baloch Z (2004) Medullary thyroid carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Vol. 8, IARC Press: Lyon, pp 86-91
27. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BA (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363: 458-460
28. Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, Martino E, Romeo G, Pacini F (1996) Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 81: 1619-1622
29. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267: 381-383
30. Santoro M, Melillo RM, Carlomagno F, Fusco A, Vecchio G (2002) Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci 963: 116-121
31. Schilling T, Bürck J, Sinn HP, Clemens A, Otto HF, Höppner W, Herfarth C, Ziegler R, Schwab M, Raue F (2001) Prognostic value of codon 918 (ATG→ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 95: 62 - 66
32. Schröder S, Böcker W, Baisch H, Bürk CG, Arps H, Meiners I, Kastendieck H, Heitz PU, Klöppel G (1988) Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immuno-cytochemistry, and DNA content. Cancer 61: 806-816
33. Scurini C, Quadro L, Fattoruso O, Verga U, Libroia A, Lupoli G, Cascone E, Marzano L, Paracchi S, Busnardo B, Girelli ME, Bellastella A, Colantuoni V (1998) Germline and somatic mutations of the RET proto-oncogene in apparently sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 137: 51-57
34. Shan L, Nakamura M, Nakamura Y, Utsunomiya H, Shou N, Jiang X, Jing X, Yokoi T, Kakudo K (1998) Somatic mutations in the RET protooncogene in Japanese and Chinese sporadic medullary thyroid carcinomas. Jpn J Cancer Res 89: 883-886
35. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells Jr SA (2005) Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 353: 1105-1113
36. Sobin LH, Wittekind C (2002) TNM Classification of Malignant Tumours (UICC), 6th edn. John Wiley & Sons: Hoboken, New Jersey, pp 52-56
37. Uchino S, Noguchi S, Adachi M, Sato M, Yamashita H, Watanabe S, Murakami T, Toda M, Murakami N, Yamashita H (1998) Novel point mutations and allele loss at the RET locus in sporadic medullary thyroid carcinomas. Jpn J Cancer Res 89: 411 -418
38. Uchino S, Noguchi S, Yamashita H, Sato M, Adachi M, Yamashita H, Watanabe S, Ohshima A, Mitsuyama S, Iwashita T, Takahashi M (1999) Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type. Jpn J Cancer Res 90: 1231 -1237
39. Wohllk N, Cote GJ, Bugalho MM, Ordonez N, Evans DB, Goepfert H, Khorana S, Schultz P, Richards CS, Gagel RF (1996) Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81: 3740-3745
40. Zedenius J, Larsson C, Bergholm U, Bovée J, Svensson A, Hallengren B, Grimelius L, Bäckdahl M, Weber G, Wallin G (1995) Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 80: 3088-3090
41. Zedenius J, Wallin G, Hamberger B, Nordenskjöld M, Weber G, Larsson C (1994) Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTCs. Hum Mol Genet 3: 1259-1262